Bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

bluebird bio, Inc. announced today that it has completed the first commercial cell collection for LYFGENIA , a one-time gene therapy for the treatment of sickle cell disease in patients with a...

Related Keywords

Washington ,District Of Columbia ,United States ,Andrew Obenshain ,David Jacobsohn ,Marrow Transplantation At Children National Hospital ,Treatment Centers Qtcs ,Children National Hospital ,Nasdaq ,National Hospital ,Treatment Centers ,Marrow Transplantation ,Marketing Long Term Follow Up Study ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,